Innate Pharma S.A. (IPHA) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 62.9% versus a loss of 26.4%. Over five years, IPHA leads with a -74.8% price change compared with -87.2% for WHWK. Whitehawk Therapeutics is the larger company by market cap ($197.8 million vs $165.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | WHWK |
|---|---|---|
| Share price | $1.48 | $3.47 |
| Market cap | $165.32M | $197.82M |
| 1-day change | -2.63% | +1.76% |
| YTD return | -15.43% | +43.39% |
| 1-year return | -26.37% | +62.91% |
| 5-year return | -74.79% | -87.25% |
| EPS (TTM) | $-0.59 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $5.50 |
| 52-week low | $1.17 | $1.87 |
| Distance from 52-week high | -45.39% | -36.85% |
| Analyst consensus | none | buy |
| Avg. price target upside | +350.68% | +122.19% |
| Average volume | 156.96K | 367.72K |
| Shares outstanding | 111.70M | 57.01M |
| Employees | 120 | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed IPHA by 89.3 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
IPHA vs WHWK FAQ
Which is bigger, Innate Pharma S.A. or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $197.82M compared with $165.32M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, IPHA or WHWK?
WHWK returned +62.91% over the past 12 months, compared with -26.37% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Whitehawk Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Innate Pharma S.A. and Biotechnology: Pharmaceutical Preparations for Whitehawk Therapeutics.